Eli Lilly and Company $LLY Shares Acquired by PKO Investment Management Joint Stock Co

Key Points

• PKO Investment Management Joint Stock Co increased its stake in Eli Lilly and Company by 50.3%, owning 14,426 shares valued at approximately $11.25 million as of the latest SEC filing.
• Insider trading showed that Director J Erik Fyrwald purchased 1,565 shares at an average price of $642.33, increasing his total ownership to about $47.9 million.
• BMO Capital Markets raised its price target for Eli Lilly from $840 to $930, contributing to the consensus target price of $938.61 among analysts.

PKO Investment Management Joint Stock Co lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 50.3% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 14,426 shares of the company's stock after buying an additional 4,826 shares during the period. Eli Lilly and Company accounts for approximately 1.2% of PKO Investment Management Joint Stock Co's holdings, making the stock its 20th biggest position. PKO Investment Management Joint Stock Co's holdings in Eli Lilly and Company were worth $11,245,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. WestEnd Advisors LLC lifted its position in shares of Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after acquiring an additional 21 shares during the last quarter. Wealth Preservation Advisors LLC acquired a new position in Eli Lilly and Company in the 1st quarter valued at $27,000. Blume Capital Management Inc. grew its stake in Eli Lilly and Company by 46.7% in the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company's stock valued at $34,000 after buying an additional 14 shares during the last quarter. Citizens National Bank Trust Department boosted its holdings in Eli Lilly and Company by 180.0% in the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after purchasing an additional 27 shares during the period. Finally, IMG Wealth Management Inc. bought a new position in shares of Eli Lilly and Company during the 2nd quarter worth about $35,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director J Erik Fyrwald acquired 1,565 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the transaction, the director owned 74,578 shares in the company, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jamere Jackson purchased 200 shares of Eli Lilly and Company stock in a transaction on Friday, August 8th. The shares were acquired at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the transaction, the director directly owned 9,402 shares of the company's stock, valued at approximately $6,013,143.12. The trade was a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased a total of 4,514 shares of company stock worth $2,894,841 in the last ninety days. 0.13% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have recently issued reports on LLY. BMO Capital Markets lifted their target price on shares of Eli Lilly and Company from $840.00 to $930.00 and gave the company an "outperform" rating in a research note on Monday, October 20th. Morgan Stanley cut their price objective on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an "overweight" rating on the stock in a research report on Friday, October 3rd. Leerink Partners reaffirmed a "market perform" rating and set a $715.00 price target on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Hsbc Global Res upgraded shares of Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research note on Wednesday, August 27th. Finally, Guggenheim reiterated a "buy" rating and set a $948.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, October 16th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company currently has an average rating of "Moderate Buy" and a consensus target price of $938.61.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $825.86 on Friday. The company has a fifty day moving average of $768.01 and a 200-day moving average of $768.14. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $935.63. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The firm has a market capitalization of $781.65 billion, a P/E ratio of 53.98, a P/E/G ratio of 1.18 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company's revenue was up 37.6% compared to the same quarter last year. During the same quarter last year, the firm posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.